Initiator Pharma A/S (INIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Initiator Pharma A/S (INIT) has a cash flow conversion efficiency ratio of -0.144x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.68 Million ≈ $-504.13K USD) by net assets (Skr32.47 Million ≈ $3.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Initiator Pharma A/S net asset quality index to measure how much of total assets are equity-financed.
Initiator Pharma A/S - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Initiator Pharma A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INIT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Initiator Pharma A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Initiator Pharma A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
K Wave Media Ltd.
NASDAQ:KWM
|
-166.159x |
|
Innovative Rfk SpA
PA:MLIRF
|
-0.025x |
|
Hyterra Ltd
AU:HYT
|
-0.032x |
|
Burcon NutraScience Corporation
TO:BU
|
0.640x |
|
Legend Mining Ltd
AU:LEG
|
-0.023x |
|
Safeture AB
ST:SFTR
|
0.096x |
|
Madhav Copper Limited
NSE:MCL
|
0.181x |
|
OneConstruction Group Limited Ordinary Shares
NASDAQ:ONEG
|
-0.837x |
Annual Cash Flow Conversion Efficiency for Initiator Pharma A/S (2016–2024)
The table below shows the annual cash flow conversion efficiency of Initiator Pharma A/S from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Initiator Pharma A/S market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr14.78 Million ≈ $1.59 Million |
Skr-12.08 Million ≈ $-1.30 Million |
-0.817x | +48.31% |
| 2023-12-31 | Skr11.16 Million ≈ $1.20 Million |
Skr-17.65 Million ≈ $-1.90 Million |
-1.581x | -64.49% |
| 2022-12-31 | Skr34.02 Million ≈ $3.66 Million |
Skr-32.70 Million ≈ $-3.52 Million |
-0.961x | +1.36% |
| 2021-12-31 | Skr34.99 Million ≈ $3.77 Million |
Skr-34.10 Million ≈ $-3.67 Million |
-0.974x | -74.10% |
| 2020-12-31 | Skr14.41 Million ≈ $1.55 Million |
Skr-8.06 Million ≈ $-867.82K |
-0.560x | +35.17% |
| 2019-12-31 | Skr9.91 Million ≈ $1.07 Million |
Skr-8.55 Million ≈ $-920.44K |
-0.863x | -5.32% |
| 2018-12-31 | Skr16.57 Million ≈ $1.78 Million |
Skr-13.58 Million ≈ $-1.46 Million |
-0.820x | +37.20% |
| 2017-12-31 | Skr5.96 Million ≈ $641.82K |
Skr-7.78 Million ≈ $-837.68K |
-1.305x | -372.03% |
| 2016-12-31 | Skr-371.00K ≈ $-39.93K |
Skr-178.00K ≈ $-19.16K |
0.480x | -- |
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more